Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MPC-3100

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Various types of Hsp90 inhibitors have been and continue to undergo clinical investigation. One development candidate is the… Expand
Is this relevant?
2012
2012
Modulation of Hsp90 (heat shock protein 90) function has been recognized as an attractive approach for cancer treatment, since… Expand
Is this relevant?
2011
2011
Background: MPC-3100 is an orally-bioavailable, fully-synthetic inhibitor of the molecular chaperone HSP90. HSP90 is important… Expand
Is this relevant?
2011
2011
MPC-3100 is a synthetic, orally bioavailable HSP90 inhibitor in clinical development. The low solubility of this compound… Expand
Is this relevant?
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: MPC-3100 is a fully synthetic, orally… Expand
Is this relevant?
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL MPC-3100, an 8, 9-disubstituted purine, is an orally… Expand
Is this relevant?
2011
2011
e13016 Background: MPC-3100, an orally bioavailable synthetic inhibitor of HSP90, has demonstrated efficacy in animal models and… Expand
Is this relevant?
2011
2011
Introduction: MPC-3100 is a fully synthetic, orally bioavailable, Hsp90 inhibitor in clinical development. It is broadly active… Expand
Is this relevant?
2011
2011
e13019 Background: MPC-3100 is an oral synthetic inhibitor of HSP90, in a phase I safety study in cancer patients. Major… Expand
Is this relevant?
2010
2010
e13112 Background: MPC-3100 is a fully synthetic, orally bioavailable, Hsp90 inhibitor developed by Myriad Pharmaceuticals, Inc… Expand
Is this relevant?